Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

Novo Nordisk A/S6,500 enrolled

Overview

This study is conducted in Europe. An observational study evaluating the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for treatment of Type 2 diabetes mellitus in Czech Republic.

Study Type

OBSERVATIONAL

Enrollment

6,500

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Intervention at the discretion of the physician

insulin detemirDRUG

Intervention at the discretion of the physician

biphasic insulin aspart 30DRUG

Intervention at the discretion of the physician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Current treatment with human soluble insulin, insulin NPH or premixed human insulin * The selection of the subjects will be at the discretion of the individual physician Exclusion Criteria: * Current treatment with insulin aspart, insulin detemir or biphasic insulin aspart 30 * Previous enrolment in this study * Hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients. * Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months and considered to be treated by biphasic insulin aspart 30 or insulin detemir

Locations (1)

Novo Nordisk Investigational Site

Prague, Czechia

Outcomes

Primary Outcomes

HbA1c after switch from human insulin to modern insulin treatment

Time frame: After 24 weeks

Secondary Outcomes

Percentage of subjects to reach HbA1c below 7.0% and = 6.5% at approximately 12 weeks and 24 weeks of treatment